Kerns RJ - Search Results

1

N-Arylacyl O-sulfonated aminoglycosides as novel inhibitors of human neutrophil elastase, cathepsin G and proteinase 3.

Craciun I, Fenner AM, Kerns RJ. Craciun I, et al. Among authors: kerns rj. Glycobiology. 2016 Jul;26(7):701-709. doi: 10.1093/glycob/cww011. Epub 2016 Feb 5. Glycobiology. 2016. PMID: 26850997 Free PMC article.

2

Synthesis, separation, and characterization of amphiphilic sulfated oligosaccharides enabled by reversed-phase ion pairing LC and LC-MS methods.

Fenner AM, Kerns RJ. Fenner AM, et al. Among authors: kerns rj. Carbohydr Res. 2011 Dec 13;346(17):2792-800. doi: 10.1016/j.carres.2011.09.020. Epub 2011 Sep 24. Carbohydr Res. 2011. PMID: 22015170 Free PMC article.

3

Bioenergetic effects of mitochondrial-targeted coenzyme Q analogs in endothelial cells.

Fink BD, Herlein JA, Yorek MA, Fenner AM, Kerns RJ, Sivitz WI. Fink BD, et al. Among authors: kerns rj. J Pharmacol Exp Ther. 2012 Sep;342(3):709-19. doi: 10.1124/jpet.112.195586. Epub 2012 Jun 1. J Pharmacol Exp Ther. 2012. PMID: 22661629 Free PMC article.

4

Selective inhibition of bacterial and human topoisomerases by N-arylacyl O-sulfonated aminoglycoside derivatives.

Fenner AM, Oppegard LM, Hiasa H, Kerns RJ. Fenner AM, et al. Among authors: kerns rj. ACS Med Chem Lett. 2013 May 9;4(5):470-474. doi: 10.1021/ml3004507. ACS Med Chem Lett. 2013. PMID: 23814643 Free PMC article.

5

Novel N-1 substituted fluoroquinolones inhibit human topoisomerase I activity and exhibit anti-proliferative activity.

Oppegard LM, Delgado JL, Kulkarni CA, Towle TR, Hart DE, Williams BP, Lentz SRC, Norris BJ, Flory CM, Schumacher RJ, Murry DJ, Kerns RJ, Hiasa H. Oppegard LM, et al. Among authors: kerns rj. Invest New Drugs. 2019 Apr;37(2):378-383. doi: 10.1007/s10637-018-0666-x. Epub 2018 Sep 10. Invest New Drugs. 2019. PMID: 30198058 Free PMC article.

6

Design, synthesis, and evaluation of novel N-1 fluoroquinolone derivatives: Probing for binding contact with the active site tyrosine of gyrase.

Towle TR, Kulkarni CA, Oppegard LM, Williams BP, Picha TA, Hiasa H, Kerns RJ. Towle TR, et al. Among authors: kerns rj. Bioorg Med Chem Lett. 2018 Jun 1;28(10):1903-1910. doi: 10.1016/j.bmcl.2018.03.085. Epub 2018 Mar 30. Bioorg Med Chem Lett. 2018. PMID: 29661533 Free PMC article.

7

Probing structural requirements for human topoisomerase I inhibition by a novel N1-Biphenyl fluoroquinolone.

Delgado JL, Lentz SRC, Kulkarni CA, Chheda PR, Held HA, Hiasa H, Kerns RJ. Delgado JL, et al. Among authors: kerns rj. Eur J Med Chem. 2019 Jun 15;172:109-130. doi: 10.1016/j.ejmech.2019.03.040. Epub 2019 Mar 20. Eur J Med Chem. 2019. PMID: 30959322 Free PMC article.

8

Suppression of human T cell activation by derivatives of glycerol monolaurate.

Fosdick MG, Chheda PR, Tran PM, Wolff A, Peralta R, Zhang MY, Kerns R, Houtman JCD. Fosdick MG, et al. Sci Rep. 2021 Apr 26;11(1):8943. doi: 10.1038/s41598-021-88584-y. Sci Rep. 2021. PMID: 33903712 Free PMC article.

9

Synthesis and evaluation of PSSRI-based inhibitors of Staphylococcus aureus multidrug efflux pumps.

German N, Kaatz GW, Kerns RJ. German N, et al. Among authors: kerns rj. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1368-73. doi: 10.1016/j.bmcl.2008.01.014. Epub 2008 Jan 9. Bioorg Med Chem Lett. 2008. PMID: 18242086

10

Separation of hydroxyl protected heparin derived disaccharides using reversed-phase high-performance liquid chromatography.

Kerns RJ, Linhardt RJ. Kerns RJ, et al. J Chromatogr A. 1995 Jun 30;705(2):369-73. doi: 10.1016/0021-9673(95)00293-v. J Chromatogr A. 1995. PMID: 7640772

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

66 results

Search Page